Percutaneous image-guided therapies of primary liver tumors: Techniques and outcomes.

Percutaneous image-guided therapies of primary liver tumors: Techniques and outcomes. Presse Med. 2019 Aug 21;: Authors: Ben Ammar M, Nouri-Neuville M, Cornelis FH Abstract Embolization and percutaneous ablations became well-established therapeutic options for hepatocellular carcinomas (HCC). All are performed under minimally invasive conditions using imaging guidance. Selection of a technique over another follows guidelines but also patient's status and availability of the techniques. The aim of this review is to present these techniques performed in routine to treat HCC and to report the outcomes. PMID: 31445698 [PubMed - as supplied by publisher]
Source: Presse Medicale - Category: General Medicine Authors: Tags: Presse Med Source Type: research

Related Links:

Condition:   Hepatocellular Carcinoma Intervention:   Biological: allogeneic NK cells therapy Sponsors:   Beijing 302 Hospital;   Shenzhen Third People's Hospital;   The first People's Hospital of Zhengzhou Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 14 November 2019Source: Prostaglandins &Other Lipid MediatorsAuthor(s): Sherif M. Shoieb, Mahmoud A. El-Ghiaty, Mohammed A. Alqahtani, Ayman O.S. El-KadiAbstractHepatic inflammation is a key pathologic mediator in a wide array of acute and chronic liver diseases. Hepatitis is a crucial driver of liver tissue damage provoking the progression to severe fibrosis, cirrhosis and hepatocellular carcinoma, irrespective of the etiologic cause. Inflammatory liver diseases are collectively considered one of the most critical public health risks. Cytochrome P450 (CYP) enzymes are superfamily of ...
Source: Prostaglandins and Other Lipid Mediators - Category: Lipidology Source Type: research
The NSD family of histone lysine methyltransferases have emerged as important biomarkers that participate in a variety of malignancies. Recent evidence has indicated that somatic dysregulation of the nuclear r...
Source: Journal of Experimental and Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Research Source Type: research
imo Negrini Hepatocellular carcinoma (HCC) is a deadly disease and therapeutic efficacy in advanced HCC is limited. Since progression of chronic liver disease to HCC involves a long latency period of a few decades, a significant window of therapeutic opportunities exists for prevention of HCC and improve patient prognosis. Nonetheless, there has been no clinical advancement in instituting HCC chemopreventive strategies. Some of the major challenges are heterogenous genetic aberrations of HCC, significant modulation of tumor microenvironment and incomplete understanding of HCC tumorigenesis. To this end, animal models o...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
We present a narrative review of HCC in Africa, discussing present and future trends. [...] Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.Article in Thieme eJournals: Table of contents  |  Abstract  |  Full text
Source: Seminars in Liver Disease - Category: Gastroenterology Authors: Tags: Review Article Source Type: research
In this study, we observed that YY1 is positively correlated with microvessel density (MVD) and poor prognosis in HCC tissues. We further found that YY1 promotes the transcriptional activity of VEGFA by binding its promoter in HCC. The secreted VEGFA from HCC cells activates phosphorylation of VEGFR2 to promotes tube formation, cell migration, and invasion of vascular endothelial cells in vitro, and promotes tumor growth and angiogenesis in vivo. In addition, upregulation of YY1 enhanced resistance of bevacizumab in HCC cells. These results indicate that YY1 plays essential roles in HCC angiogenesis and resistance of bevac...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conclusions: Radiomics algorithm based on ultrasound ORF data combined with SAP technology can effectively predict MVI, which has potential clinical application value for non-invasively preoperative prediction of MVI in HCC patients.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsThe epigenetic modificator EZH2 can suppress the expression of immune checkpoint inhibitor PD-L1 by directly upregulating the promoter H3K27me3 levels ofCD274 andIRF1 in hepatoma cells, and might serve as a potential therapeutic target for combination of immunotherapy for immune-activated HCC.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
Genomic Analysis of Hepatocellular Carcinoma  (study page |release notes)
Source: dbGaP, the database of Genotypes and Phenotypes - Category: Genetics & Stem Cells Tags: StudyRelease Source Type: research
We report a rare case of primary yolk sac tumour of the prostate with extensive local and liver metastasis, the latter of which exhibited sheets of small blue cells expressing CD99 and focal sall4 on biopsy. Positivity for CD99 and gata3 in the initial biopsy raised the differential diagnosis of Ewing sarcoma and poorly differentiated carcinoma. The primary tumour demonstrated an admixture of solid and glandular growth patterns and occasional Schiller-Duval bodies. A panel of immunohistochemical stains showing positivity for AE1/3, sall4, cdx2, and focal alpha-fetoprotein, and negativity for oct-4, facilitated the diagnosi...
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research
More News: Cancer & Oncology | Carcinoma | General Medicine | Hepatocellular Carcinoma | Liver | Liver Cancer | Urology & Nephrology